Physician profile
Peter D Rivera
NPI 1073741997
$2,340.31
in general payments reported to CMS, 2019-2025
10 companies · $1,339 in 2025
The $1,339 reported for 2025 was more than what 95% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $378 · 2020: $41.81 · 2022: $187 · 2023: $50.41 · 2024: $344 · 2025: $1,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,310 · Food and Beverage: $423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,310.00 |
| Food and Beverage | $423.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $1,310.00 | 2025 | Fluid Systems - Infusion Systems |
| Merck Sharp & Dohme LLC | $256.34 | 2019-2024 | Bridion |
| Medtronic, INC. | $182.55 | 2022-2024 | Corevalve Evolut R |
| Abbott Laboratories | $179.35 | 2022-2024 | |
| Edwards Lifesciences Corporation | $167.10 | 2019-2023 | Swan-Ganz |
| Abiomed | $146.77 | 2024 | Impella |
| Pacira Pharmaceuticals Incorporated | $41.81 | 2020 | |
| Ethicon US, LLC | $29.32 | 2025 | Vistaseal, Surgiflo Hemostatic Matrix, Evarrest |
| Cvrx, INC. | $23.28 | 2023 | Barostim Neo System |
| Ambu INC. | $3.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.